ethyl (6-methoxypyridin-3-yl)acrylate | 72716-96-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl (6-methoxypyridin-3-yl)acrylate
• 英文别名: ethyl 3-(6-methoxypyridin-3-yl)prop-2-enoate；Ethyl 3-(6-methoxy-3-pyridyl)acrylate
• CAS: 72716-96-2
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: IQXXDFIZZHXWBM-UHFFFAOYSA-N

物化性质

• 熔点：
  52 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• 沸点：
  320.5±27.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (6-methoxypyridin-3-yl)acrylate 在 palladium dihydroxide 盐酸 、 4-二甲氨基吡啶 、 sodium hydroxide 、 正丁基锂 、 氢气 、 sodium acetate 、 sodium cyanoborohydride 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 正己烷 、 乙酸乙酯 、 1,2-二氯乙烷 、 异丙醇 为溶剂， 反应 64.25h， 生成 (3S)-3-(6-methoxypyridin-3-yl)-3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl}propionic acid
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent α_vβ₃ Antagonist for the Prevention and Treatment of Osteoporosis

  摘要：

  3(S)-(6-Methoxypyridin-3-yl)-3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)propyl]-imidazolidin-1-yl}propionic acid 6 was identified as a potent and selective antagonist of the alpha(v)beta(3) receptor. This compound has an excellent in vitro profile (IC50 = 0.08 nM), a significant unbound fraction in human plasma (12%), and good pharmacokinetics in rat, dog, and rhesus monkey. On the basis of the efficacy shown in three in vivo models of bone turnover, the compound was selected for clinical development. To support the ongoing metabolism and safety studies, a novel strategy was employed in which a series of oxidized derivatives of 6 were prepared by exposure of 6 (or the methyl ester) to chemical oxidizing agents. These products proved useful in the identification of active metabolites generated by either in vitro or in vivo metabolism.

  DOI：

  10.1021/jm030306r
• 作为产物：
  描述：

  6-甲氧基烟腈 在 镍 哌啶 、 吡啶 、 盐酸 、 聚合甲醛 、 氢气 、 盐酸氨基脲 、 sodium acetate 作用下， 反应 0.25h， 生成 ethyl (6-methoxypyridin-3-yl)acrylate
  参考文献：
  名称：

  Isocytosine H2-receptor histamine antagonists. IV. The synthesis and biological activity of donetidine (SK&F 93574) and related compounds

  摘要：

  The synthesis and biological activity of some novel 2-amino-4-pyrimidone derivatives is described. Side-chains associated with H-2-antagonist activity am attached through the 2-amino group, whilst a range of 2-hydroxypyridine containing moieties are substituted at the 5-position of the pyrimidone ring. Good H-2-receptor histamine antagonist activity is observed with all the series and the majority of the compounds are selective for the H-2-receptor. High aqueous solubility and iv potency coupled with an extended duration of biological activity in animal models led to compound 16c, 2-[2-(5-dimethylaminomethyl-2-furanylmethyl-thio)ethylamino]-5-(2-hydroxypyrid-4-ylmethyl)-4-pyrimidone (donetidine, SK&F 93574) being selected for clinical investigation as a potential parenterally administered therapeutic agent.

  DOI：

  10.1016/0223-5234(93)90091-r

文献信息

• [EN] NOVEL PYRAZINE AMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS PYRAZINE-AMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015018754A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

  本发明涉及式1的化合物或其药用盐，其中R1、R2、R3、R5、R6和X-具有规范中指示的含义之一，其用作药物，用于治疗呼吸道疾病或疾病和过敏性疾病，包括至少一种所述化合物或其药用盐的药物组合的制药组合。
• [EN] MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)<br/>[FR] MODULATEURS DU STIMULATEUR DES GÈNES DE L'INTERFÉRON (SING)
  申请人：RYVU THERAPEUTICS S A

  公开号：WO2019238786A1

  公开（公告）日：2019-12-19

  The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

  本发明涉及式(I)化合物及其作为STING（干扰素基因刺激剂）调节剂的盐、立体异构体、互变异构体或N-氧化物。本发明进一步涉及式(I)化合物作为药物的应用以及包含该化合物的药物组合物。
• [EN] INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE αV
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089357A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（Ia）或（Ib）的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αV-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及使用这些化合物和药物组合物治疗与αV-含有整合素失调相关的疾病、紊乱或状况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Synthesis of oxadiazole-2-oxide derivatives as potential drug candidates for schistosomiasis targeting SjTGR
  作者：Gongming Li、Qingqing Guo、Chao Feng、Huan Chen、Wenjiao Zhao、Shu Li、Yang Hong、Dequn Sun

  DOI：10.1186/s13071-021-04634-4

  日期：2021.12

  Because of the increasing drug resistance to praziquantel (PZQ), which is the primary drug for schistosomiasis, developing new drugs to treat schistosomiasis is crucial. Oxadiazole-2-oxides have been identified as potential anti-schistosomiasis reagents targeting thioredoxin glutathione reductase (TGR). In this work, one of the oxadiazole-2-oxides derivatives furoxan was used as the lead compound to

  血吸虫病是一种慢性寄生虫病，影响全世界数百万人的健康。由于治疗血吸虫病的主要药物吡喹酮（PZQ）的耐药性不断增加，开发治疗血吸虫病的新药至关重要。 2-恶二唑氧化物已被确定为针对硫氧还蛋白谷胱甘肽还原酶（TGR）的潜在抗血吸虫病试剂。本工作以恶二唑-2-氧化物衍生物呋喃酮为先导化合物，开发了一系列新型呋喃酮衍生物，用于研究对含硒重组日本血吸虫TGR（rSjTGR-Sec）和可溶性蠕虫抗原蛋白的抑制活性（SWAP）含有野生型日本血吸虫TGR（wtSjTGR），以开发新的血吸虫病先导化合物。制备了三十九种新型衍生物来测试它们对这两种酶的活性。采用对接法检测活性分子与SjTGR的结合位点。对这些新型呋喃酮衍生物的构效关系（SAR）进行了初步分析。结果发现，包括化合物 6a-6d、9ab、9bd 和 9be 在内的几种新衍生物对 rSjTGR-Sec 或含有 wtSjTGR 的 SWAP 的活性比
• [EN] 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] ACIDES PROPIONIQUES À SUBSTITUTION EN POSITION 3 EN TANT QU'INHIBITEURS D'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089353A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αν- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay- containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了化合物的公式(I)：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αν-含有整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物和使用这些化合物和药物组合物来治疗与ay-含有整合素失调相关的疾病、疾病或症状的方法，例如病理纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。